S. Korea, U.S. To Join In Producing Stem-Cell Based H1N1 Vaccine
This article was originally published in PharmAsia News
Executive SummarySouth Korea and the United States have agreed to collaborate in producing an H1N1 flu vaccine using stem cell research over the next three or four years. South Korea's health minister and the U.S. secretary of Health and Human Services agreed at a meeting in Washington to aim for mass production of vaccines. The H1N1 virus is spreading quickly in South Korea as well as the rest of Southeast Asia. (Click here for more
You may also be interested in...
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.